34493-98-6 Usage
Originator
Panimycin,Meiji Seika,Meiji Seika,1975
Uses
Dideoxykanamycin B is an antibacterial compound.
Definition
ChEBI: A kanamycin that is kanamycin B lacking the 3- and 4-hydroxy groups on the 2,6-diaminosugar ring.
Manufacturing Process
Penta-N-benzyloxycarbonyl-2"-O-benzylsulfonyl-3',4'-dideoxy-3'-enokanamycin B (61 mg) was dissolved in about 18 ml of liquid ammonia at -
50°C, followed by addition of about 120 mg of metal sodium. The mixture was
gently stirred at -50°C for 1 hour, followed by addition of methanol to
consume up the excess of the metal sodium. The reaction mixture was
allowed to slowly raise up to ambient temperature while permitting the
ammonia to evaporate. The residue so obtained was dissolved in water, and
the aqueous solution was admixed with 4 ml of a cation-exchange resin,
Dowex 50WX2 (H cycle) (a product of Dow Chemical Co., USA) under stirring.
The admixture comprising the resin was placed on the top of a column of 3,5
ml of the same resin. Dowex 50WX2, and the whole resin column was well
washed with water and then eluted using 1 M aqueous ammonia as the
developing solvent. The eluate was collected in fractions, and such fractions
which gave positive reaction with ninhydrin were combined together and
concentrated to dryness, affording 3',4'-dideoxy-3'-eno-kanamycin B in the
form of its monocarbonate. The yield was 23,8 mg (97%).The product (12.1 mg) obtained in the above step was dissolved in 0.3 ml of
water, to which was then added a catalytic quantity (about 5 mg) of platinum
oxide. Hydrogenation was made with hydrogen gas at a pressure of 3.5
kg/cm2 for 1? hours. The reaction solution was filtered to remove the
catalyst, and the filtrate was concentrated to dryness, giving the desired
product 3',4'-dideoxykanamycin B in the form of its monocarbonate. The yield
was 11.5 mg (95%). [α]D25 +110° (c 1, water). The overall yield of 3',4'-
dideoxykanamycin B based on the starting kanamycin B was 57%.
Therapeutic Function
Antibacterial
Antimicrobial activity
3′,4′-Dideoxy kanamycin B. A semisynthetic aminoglycoside
closely related to the natural compound tobramycin (3′-deoxy
kanamycin B). Supplied as the sulfate.
It is active against staphylococci including methicillinresistant
strains, a wide range of enterobacteria, Acinetobacter
and Pseudomonas spp. It is also active against M. tuberculosis
and the M. avium complex (MICs 4–16 mg/L). It exhibits
the usual aminoglycoside properties of bactericidal activity
at concentrations close to the MIC and bactericidal synergy
with selected β-lactam antibiotics.
Absence of hydroxyl groups present in the parent kanamycin
B renders dibekacin resistant to phosphorylation
by APH(3′). It is also resistant to some forms of ANT(4′).
However, the type of this enzyme, ANT(4′), found in
some Gram-positive organisms modifies dibekacin at the
2″-hydroxyl group; nevertheless dibekacin has much greater
activity than tobramycin against organisms that produce the
enzyme.
A 1 mg/kg intravenous bolus dose achieves a peak plasma
concentration of around 5 mg/L. The plasma half-life is
2.3 h. Protein binding is 3–12%. It is eliminated principally
by the renal route, 75–80% of the dose appearing in
the urine in the first 24 h. Elimination is inversely related to
renal function. In patients maintained on chronic hemodialysis,
the half-life rises to 54 h between dialyses and falls to
6–7 h on dialysis.
Toxic effects are those typical of aminoglycosides with a
frequency similar to or less than those of gentamicin.
It is used for severe infections caused by susceptible microorganisms,
especially those resistant to established aminoglycosides,
but availability is limited.
Safety Profile
Poison by
intraperitoneal, subcutaneous, intramuscular,
and intravenous routes. Moderately toxic by
ingestion. Experimental teratogenic and
reproductive effects. An antibacterial agent.
When heated to decomposition it emits
toxic fumes of NOx.
Check Digit Verification of cas no
The CAS Registry Mumber 34493-98-6 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,4,4,9 and 3 respectively; the second part has 2 digits, 9 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 34493-98:
(7*3)+(6*4)+(5*4)+(4*9)+(3*3)+(2*9)+(1*8)=136
136 % 10 = 6
So 34493-98-6 is a valid CAS Registry Number.
InChI:InChI=1/C18H37N5O8.H2O4S/c19-4-6-1-2-7(20)17(28-6)30-15-8(21)3-9(22)16(14(15)27)31-18-13(26)11(23)12(25)10(5-24)29-18;1-5(2,3)4/h6-18,24-27H,1-5,19-23H2;(H2,1,2,3,4)/t6-,7+,8-,9+,10+,11-,12+,13+,14-,15+,16-,17+,18+;/m0./s1
34493-98-6Relevant articles and documents
Method for synthesizing arab League Beica starbeica star and
-
Paragraph 0079, (2017/01/19)
The present invention relates to a method for synthesizing dibekacin and arbekacin. The method comprises: using kanamycin B as an initial raw material, protecting five amino groups of the kanamycin B by using t-butyloxycarboryl, protecting hydroxyl of positions 4''and 6'' by aldol condensation, eliminating, in the presence of 2,4,5-triiodo-imidazol, triphenylphosphine, and imidazole, hydroxyl of positions 3' and 4' to form a double bond, removing the protection of the amino groups and the hydroxyl in a hydrochloric methanol solution, and performing catalytic hydrogenation to obtain dibekacin; and using 3',4'-didanosine-3', 4'-didehydro-kanamycin B as a raw material, protecting all the amino groups and hydroxyl by using trimethylsilyl acetate, acylating an amino group of a position 1 by using synthesized active ester, removing the protected groups by sequentially using hydrochloric acid and hydrazine hydrate, and finally, performing catalytic hydrogenation to obtain arbekacin. The synthesizing method is simple in operation, high in yield, environmentally-friendly, low in production cost, and beneficial to industrial production.
An improved synthesis of 3',4'-dideoxykanamycin B
Matsuno, Tomio,Yoneta, Toshio,Fukatsu, Shunzo,Umemura, Eijiro
, p. 271 - 275 (2007/10/02)
-
3',4'-Episulfido kanamycin B compounds
-
, (2008/06/13)
New routes are provided for the synthesis of 3',4'-dideoxykanamycin B which is effective in inhibiting kanamycin-resistant organisms from kanamycin B through new intermediate, of which a fundamental process comprises a new reaction of a 3',4'-epoxy derivative of amino- and hydroxyl-protected kanamycin B with a xanthate to form a corresponding 3',4'-dideoxy-3'-eno derivative followed by removal of the amino- and hydroxyl-protecting groups thereof and by hydrogenation of the resulting 3',4'-dideoxy-3'-eno-kanamycin B. A 3',4'-episulfide derivative corresponding to the 3',4'-epoxy derivative which is formed as second product in the reaction of 3',4'-epoxy derivative with xanthate is also used as intermediate for the preparation of 3',4'-dideoxykanamycin B.
